Jiang Y, Pannell R, Liu J N, Gurewich V
Institute for the Prevention of Cardiovascular Disease, Deaconess Hospital, Harvard Medical School, Boston, MA, USA.
Blood. 1996 Apr 1;87(7):2775-81.
Endogenous urokinase-type plasminogen activator (u-PA) has been identified in platelet membrane, and platelets have been shown to take up exogenous high molecular weight u-PA from the ambient medium. In this report, the mechanism of the association of u-PA with platelets was investigated using recombinant, single chain u-PA. When gel filtered human platelets were incubated with radiolabeled u-PA, the u-PA was found to specifically and saturably bind to the resting platelets in a dose-dependent manner. Unlabeled u-PA and the amino terminal fragment of u-PA inhibited 125I-u-PA binding to platelets with a mean IC50 of 65 and 58 nmol/L, respectively. A single saturable binding site in intact resting platelets was found with a mean kd of 43 +/- 25 nmol/L and 2263 +/- 809 sites per platelet. In contrast to resting platelets, 125I-u-PA did not bind to thrombin-induced platelets. Western blotting studies, using a monoclonal or a polyclonal antibody specific for the u-PA cell-surface receptor (u- PAR), failed to show evidence of u-PAR in resting platelets, whereas, u-PAR was found at approximately 54 and approximately 48 kD on U937 monocytes, which served as a positive control. Ligand blotting of platelet membrane and of U937 cell proteins with 125I-u-PA revealed a u-PA binding protein of approximately 70 kD in the platelets and one of approximately 54 kD in the U937 cells. Complexion of u-PA with a platelet membrane protein was also shown by gel filtration of a mixture of u-PA and platelet membrane proteins. A u-PA complex was further shown by enzyme-linked immunosorbent assay when microtiter plates were coated with platelet membrane proteins, and this complex formation was shown to be dose-dependent and saturable with an apparent kd of 17 nmol/L. It was concluded that platelet membrane contains a specific, high affinity u-PA-binding protein that is distinct from u-PAR.
内源性尿激酶型纤溶酶原激活剂(u-PA)已在血小板膜中被鉴定出来,并且已表明血小板能从周围介质中摄取外源性高分子量u-PA。在本报告中,使用重组单链u-PA研究了u-PA与血小板结合的机制。当将经凝胶过滤的人血小板与放射性标记的u-PA一起孵育时,发现u-PA以剂量依赖的方式特异性且饱和地结合到静息血小板上。未标记的u-PA和u-PA的氨基末端片段分别以平均IC50为65和58 nmol/L抑制125I-u-PA与血小板的结合。在完整的静息血小板中发现了一个单一的饱和结合位点,平均kd为43±25 nmol/L,每个血小板有2263±809个位点。与静息血小板相反,125I-u-PA不与凝血酶诱导的血小板结合。使用针对u-PA细胞表面受体(u-PAR)的单克隆或多克隆抗体进行的蛋白质印迹研究未能显示静息血小板中有u-PAR的证据,而在用作阳性对照的U937单核细胞上,在约54 kD和约48 kD处发现了u-PAR。用125I-u-PA对血小板膜和U937细胞蛋白进行配体印迹显示,血小板中有一个约70 kD的u-PA结合蛋白,U937细胞中有一个约54 kD的u-PA结合蛋白。通过对u-PA和血小板膜蛋白混合物进行凝胶过滤,也显示了u-PA与血小板膜蛋白的结合。当用血小板膜蛋白包被微量滴定板时,酶联免疫吸附测定进一步显示了一种u-PA复合物,并且这种复合物的形成呈剂量依赖性且饱和,表观kd为17 nmol/L。得出的结论是,血小板膜含有一种与u-PAR不同的特异性、高亲和力u-PA结合蛋白。